Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 07/31/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.    Case No. 18-10518 (KG)
Debtor    Reporting Period: June 1, 2018 - June 30, 2018

MOR - 1

Consolidated Schedule of Cash Receipts and Disbursements (1)

For the Period: June 1, 2018 - June 30, 2018

(Unaudited)

 

$ USD ‘000s

   June 1, 2018 - June 30, 2018     Cumulative
Since Filing
 

Beginning Cash Balance (Book)

   $ 17,109     $ 21,372  

Receipts

    

Operating Receipts

     14,773       48,732  

Miscellaneous Receipts

     24       254  
  

 

 

   

 

 

 

Total Receipts

     14,796       48,985  

Operating Disbursements

    

Payroll & Benefits / Contractors

     (2,419     (8,888

Inventory

     (1,146     (3,412

Manufacturing and Logistics

     (43     (120

Gross to Net Disbursements

     (9,590     (29,531

Marketing / Commercial Operations

     (1,102     (15,471

Ordinary Course Professionals

     (212     (498

Rent / Facilities / Equipment

     (138     (417

Insurance

     (76     (228

IT / Utilities

     (68     (242

Regulatory and Compliance

     (99     (385

Other G&A

     (253     (657
  

 

 

   

 

 

 

Total Operating Disbursements

     (15,144     (59,849

Operating Cash Flow

     (347     (10,864

Reorganization Costs

    

DIP Loan Interest and Fees

     (440     (726

US Trustee Fees

     —         (121

Restructuring Professional Fees

     (659     (1,099
  

 

 

   

 

 

 

Total Reorganization Costs

     (1,100     (1,946

Total Disbursements

   $ (16,244   $ (61,795
  

 

 

   

 

 

 

Lender Professional Fees

     (44     (545

Net Cash Flow

   $ (1,492   $ (13,354

DIP Draw - Cash

     —         7,600  
  

 

 

   

 

 

 

Ending Cash Balance (Book)

   $ 15,618     $ 15,618  

Notes:

 

(1)

The Schedule of Cash Receipts and Disbursements is presented on a book basis.